Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
about
Natural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewPotential drug-drug interactions in Alzheimer patients with behavioral symptomsAnti-dementia medications: current prescriptions in clinical practice and new agents in progressAlzheimer's therapeutics: translation of preclinical science to clinical drug developmentVitamin D, cognitive dysfunction and dementia in older adultsParkinson Disease and Dementia.A randomized controlled trial of an enhanced interdisciplinary community based group program for people with Parkinson's disease: study rationale and protocol.Nimodipine improves regional cerebral blood flow and suppresses inflammatory factors in the hippocampus of rats with vascular dementia.Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Psychotropic Drug-Related Fall Incidents in Nursing Home Residents Living in the Eastern Part of The NetherlandsThe use of life stories and its influence on persons with dementia, their relatives and staff - a systematic mixed studies reviewUse of antidementia drugs in frontotemporal lobar degeneration.Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.The impact of Medicare prescription drug coverage on the use of antidementia drugs.Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disordersDonepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial.Vascular cognitive impairment: disease mechanisms and therapeutic implications.Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectivesGuidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review.Diagnosis and management of behavioral issues in frontotemporal dementiaStructured approach to patients with memory difficulties in family practiceThe projected effect of risk factor reduction on Alzheimer's disease prevalence.The Relieving Effects of BrainPower Advanced, a Dietary Supplement, in Older Adults with Subjective Memory Complaints: A Randomized, Double-Blind, Placebo-Controlled TrialBehavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasiaDiabetes-induced central neuritic dystrophy and cognitive deficits are associated with the formation of oligomeric reticulon-3 via oxidative stress.Frontotemporal lobar degeneration: current perspectives.Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke.Brain rust: recent discoveries on the role of oxidative stress in neurodegenerative diseases.Progress in frontotemporal dementia research.Diagnosis and management of the patient with suspected dementia in primary care.Understanding and preventing the development of post-stroke dementia.Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease.Effects of repetitive transcranial magnetic stimulation on improvement of cognition in elderly patients with cognitive impairment: a systematic review and meta-analysis.Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit.Periodontitis as a Modifiable Risk Factor for Dementia: A Nationwide Population-Based Cohort Study.Nonmedical treatment of patients with dementia.α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy BodiesNo Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease.
P2860
Q26750581-C8CA7A50-47BD-428C-A44D-0CF23458D90DQ26782490-E94B51F0-0533-458E-93F0-8AB23EE96537Q26795400-4559038C-5D0E-4629-8263-34FA500DCFB7Q26829267-C6FA67C8-B915-4976-B354-B47E23252F56Q28244118-4DEE5424-2EFC-45AE-B3BA-67764C5EF8DEQ30248574-C2567577-F36D-4460-AF52-5D06AE2BC076Q30467565-875B3774-5933-4C25-BA6A-430A97434DA1Q30558416-39283D36-8353-465E-B9EE-B5E444230CCFQ31155412-5F9B52C4-39F3-4648-B18B-9556E45743DCQ33165693-15E20555-48B7-4F8F-A728-ABA1528D82FDQ33665181-35EE4AF2-FBD3-43AD-A42A-B92CD765F35DQ33759365-C2AF724F-5712-4D57-A57E-F3E7B11AAC99Q34273321-7BAC5B80-2475-4E7A-B9EC-4617E8A5DA15Q34301111-F92E6591-1357-4650-91C5-167A30A97AD8Q34690333-D1A13252-B36C-4115-9EDB-2EDB7AD088DFQ35087574-07DC9EF1-8D55-4A38-8CDD-5775AE340B3FQ35114379-5EA9DFCC-BF77-4468-A930-5271A9DF4E65Q35197111-4EFC6D0A-8DDE-440E-9FBC-56ADAFA2BA4EQ35608958-20C6BCD2-ABFB-4B9D-9222-22CE485D6CFDQ36204169-38F5F17D-A1EC-4964-A4FD-848E3AA5217EQ36238717-2F92CBB4-BA7D-4302-87E3-F5CEF9F403AFQ36680461-5EFDBB74-7F67-41F3-AE28-CC63D903902DQ36825862-97FA6F06-1A91-4911-A67C-26E990B7A62DQ36829198-2B725711-44D9-4765-B4BC-B7C11340D27BQ36861930-BF578700-BDF9-4E8E-AC7C-A93A11CF5DA3Q36890582-077B69E2-1A70-43C3-9F31-582EF46E05BFQ37591327-082C06E7-519B-4B7E-90BD-5CCFCCB6A4DFQ37686919-F0704B1F-9F21-48DD-9E77-C69A60FAE5E8Q38009974-EEFDDF27-F6FD-42CD-A5DC-0209A72B84FBQ38065721-8BCFC56F-99D0-4EFC-9002-0323BFEBAEE2Q38115210-A5119C3E-7EEF-4165-BF2F-84EB3D5F52ABQ38238144-92805479-E961-449D-9F8C-6D8637A6BFE7Q38672178-1D4A0EF7-50BD-420A-BC27-EBE921E5EBB9Q39298307-A60645FB-71D0-40F3-8790-176504EE4B3DQ39466063-DFFEC9EE-DEC4-46C5-ACAE-0E00823F9261Q40156982-58E33935-6887-4CFE-94D9-AEE4E2CD9BD9Q40522716-B1AB83E5-E64F-4D9C-9E1E-A3C84DCD9F46Q42176159-85A8E5F1-E563-4602-AA9B-7094CB01F363Q42530506-25692912-589A-488B-9A17-A39AEB95BE65Q46631793-F11113E0-277D-46AE-84DB-DBBC12AE680D
P2860
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Clinical practice with anti-de ...... iation for Psychopharmacology.
@en
Clinical practice with anti-dementia drugs: a revised
@nl
type
label
Clinical practice with anti-de ...... iation for Psychopharmacology.
@en
Clinical practice with anti-dementia drugs: a revised
@nl
prefLabel
Clinical practice with anti-de ...... iation for Psychopharmacology.
@en
Clinical practice with anti-dementia drugs: a revised
@nl
P2860
P356
P1476
Clinical practice with anti-de ...... iation for Psychopharmacology.
@en
P2093
BAP Dementia Consensus Group
P2860
P304
P356
10.1177/0269881110387547
P407
P577
2010-11-18T00:00:00Z